Table 1 Baseline demographics and clinical characteristics of participants
Control (n = 25) | Exercise (n = 24) | p-value | |
|---|---|---|---|
Female, n (%) | 21 (84%) | 19 (79%) | 0.73 |
Mean age (years) ± SD | 70 ± 2.4 | 69 ± 2.7 | 0.17 |
Disease duration, median ± IQR | 20 (11–24) | 13 (9.3–19) | 0.06 |
HAQ-DI, median ± IQR | 0.50 (0.25–0.94) | 0.19 (0.0–0.84) | 0.06 |
ESR, median ± IQR | 10 (7.0–17.5) | 11 (4.3–20.8) | 0.69 |
CRP, median ± IQR | 2 (1–5) | 3 (1–3) | 0.58 |
DAS28, median ± IQR | 2.3 (1.6–3.3) | 2.2 (1.2–3.2) | 0.78 |
ACPA+ | 16 (64%) | 20 (83%) | 0.20 |
RF+ | 20 (80%) | 19 (79%) | > 0.99 |
DMARDs | 18 (72%) | 22 (92%) | 0.14 |
Methotrexate | 15 (60%) | 21 (88%) | 0.0507 |
Methotrexate (dose), median + IQR | 15 (12.5–20) | 20 (15–25) | 0.10 |
Biologics | 12 (48%) | 9 (38%) | 0.57 |
TNF inhibitors | 6 (24%) | 8 (33%) | 0.54 |
Rituximab | 3 (12%) | 1 (4%) | 0.61 |
NSAIDs | 17 (68%) | 13 (54%) | 0.39 |
Corticosteroid use | 3 (12%) | 1 (4%) | 0.61 |
Cardiovascular diseases | 5 (20%) | 5 (21%) | > 0.99 |
Previous malignancy | 4 (16%) | 8 (33%) | 0.20 |
Lung disease | 1 (4%) | 1 (4%) | > 0.99 |
Never-smokers | 9 (36%) | 10 (42%) | 0.77 |
Smokers | 2 (8%) | 1 (4%) | > 0.99 |
Ex-smokers | 14 (56%) | 13 (54%) | > 0.99 |